Interim results from an open-label extension study of briakinumab for the treatment of moderate to severe psoriasis

被引：0
|
作者：
Langley, Richard G. [1 ]
Williams, David [2 ]
Papp, Kim [3 ]
Olds, Michele [2 ]
机构：
[1] Dalhousie Univ, Halifax, NS, Canada
[2] Abbott Labs, Abbott Pk, IL 60064 USA
[3] Prob Med Res, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2012年 / 66卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
下载
收藏
页码：AB195 / AB195
页数：1
相关论文
共 50 条
  • [41] Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
    McKevitt, N.
    Rich, P.
    Langley, R. G.
    Menter, A.
    Krueger, G.
    Zhu, B.
    Wei, H.
    Cameron, G. S.
    Heffernan, M. P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 50 - 50
  • [42] Results from an open-label extension study of etanercept in ankylosing spondylitis
    Davis, J
    Webb, A
    Lund, S
    Sack, K
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (02): : 302 - 304
  • [43] Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis
    Au, Shiu-Chung
    Goldminz, Ari M.
    Kim, Noori
    Dumont, Nicole
    Michelon, Melissa
    Volf, Eva
    Hession, Meghan
    Lizzul, Paul F.
    Andrews, Israel D.
    Kerensky, Todd
    Wang, Andrew
    Yaniv, Shimrat
    Gottlieb, Alice B.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (03) : 179 - 187
  • [44] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
    Valenzuela, F.
    Korman, N. J.
    Bissonnette, R.
    Bakos, N.
    Tsai, T. -F.
    Harper, M. K.
    Ports, W. C.
    Tan, H.
    Tallman, A.
    Valdez, H.
    Gardner, A. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
  • [45] Ixekizumab treatment improves nail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized and controlled as well as open-label phases of UNCOVER-3
    van de Kerkhof, P.
    Guenther, L.
    Gottlieb, A.
    Sebastian, M.
    Wu, J.
    Foley, P.
    Morita, A.
    Goldblum, O.
    Zhang, L.
    Erickson, J.
    Ball, S.
    Rich, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 69 - 69
  • [46] Topical use of calcitriol 3 μg/g ointment in the treatment of mild-to-moderate psoriasis:: results from an open-label study
    Carboni, I
    de Felice, C
    Bergamin, A
    Chimenti, S
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 : 11 - 13
  • [47] Open-label study of alefacept in the treatment of palmoplandar psoriasis
    Pearce, D
    Feldman, S
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (01) : A7 - A7
  • [48] Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
    Gordon, Kenneth
    Papp, Kim
    Poulin, Yves
    Gu, Yihua
    Rozzo, Stephen
    Sasso, Eric H.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (02) : 241 - 251
  • [49] Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal A.
    Zhang, Meng
    Ozturk, Zafer E.
    Shumel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1608 - 1616
  • [50] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Papp, Kim A.
    de Vente, Saskia
    Zeng, Jiewei
    Flack, Mary
    Padilla, Byron
    Tyring, Stephen K.
    DERMATOLOGY AND THERAPY, 2021, 11 (02) : 487 - 497
12345